课题基金 / 基金详情

Development of CAR T cell-based immunotherapy for high risk medulloblastoma informed by membrane proteomics

Development of CAR T cell-based immunotherapy for high risk medulloblastoma informed by membrane proteomics
基于膜蛋白质组学的高危髓母细胞瘤 CAR T 细胞免疫疗法的开发
批准号:
454536
负责人:
Delaidelli Alberto
金额:
$1.09万
依托单位国家:
加拿大
项目类别:
Fellowship Programs
财政年份:
2021
资助国家:
加拿大
项目状态:
已结题
起止时间:
2021-10-01 至 2022-02-01
关键词:

项目摘要

项目成果

Delaidelli Alberto的其他基金

相似基金

相关文献

中文摘要
翻译
脑癌是最常见的儿科实体癌,每年有5000多名儿童及其家人的生命受到破坏。然而,目前的放化疗方法往往是无效的,并导致严重的副作用,发展中的B
英文摘要
Brain cancer is the most common pediatric solid cancer, devastating the lives of more than 5.000 children and their families every year. However, current chemoradiotherapy approaches are often ineffective and cause serious side effects on the developing b
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting metabolic adaptation in MYC driven medulloblastoma
Role of the let7-eEF2K axis in MYC-driven Medulloblastoma Adaptation to Nutrient Deprivation
Targeting metabolic adaptation in MYC driven pediatric neuronal tumors
Eukaryotic Elongation Factor-2 Kinase (eEF2K) as a new therapeutic target in pediatric brain cancer
  • 批准号:
    397056
  • 项目类别:
    Fellowship Programs
  • 资助金额:
    $9.83万
  • 财政年份:
    2018
  • 负责人:
    Delaidelli Alberto
  • 依托单位:
海外基金